Drugs / Staphylococcus Aureus Immune Globulin (Human)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00066989 | Jul 2003 → Aug 2004 | staphylococcal infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Staphylococcus Aureus Immune Globulin (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00066989 ↗ |
| Known as | Altastaph | “Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates” NCT00066989 ↗ |
| Modality | Protein / enzyme biologic | “Altastaph, a human immunoglobulin product” NCT00066989 ↗ |
| Route | Intravenous | “two intravenous infusions of Altastaph” NCT00066989 ↗ |